-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $220

Benzinga·04/22/2026 20:41:40
Listen to the news
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $210 to $220.